Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT03008044 Completed - Healthy Subjects Clinical Trials

Evaluation of a Percutaneous Optical Fibre Glucose Sensor (FiberSense System)

Start date: August 2016
Phase: N/A
Study type: Interventional

This is a single center prospective study. The purpose of this study is to assess the performance of FiberSense system across the glucose measurement ranges (from hypoglycemia to hyperglycemia) as compared with a gold standard reference laboratory method (YSI glucose) in healthy volunteers.

NCT ID: NCT02993055 Completed - Healthy Subjects Clinical Trials

A Study to Assess Ulimorelin in Healthy Subjects

Start date: January 2015
Phase: Phase 1
Study type: Interventional

A Phase I dose escalation study involving healthy subjects.

NCT ID: NCT02976337 Completed - Healthy Subjects Clinical Trials

Effect of High-dose Naloxone Following Third Molar Extraction

TME
Start date: October 12, 2017
Phase: Phase 2
Study type: Interventional

Recent studies have focused on the role of endogenous opioids on central sensitization. Central sensitization is known to be impaired or altered in chronic pain conditions, as fibromyalgia or chronic tension headache. Animal studies have shown reinstatement of mechanical hypersensitivity following naloxone administration after resolution of an injury. This suggests latent sensitization. In the present study, the investigators hypothesize that a high-dose target-controlled naloxone infusion (total dose: 3.25 mg/kg) can reinstate pain and hyperalgesia 6-8 weeks after a unilateral primary open groin hernia repair procedure. The investigators aim to show that latent sensitization is present in humans and is modulated by endogenous opioids.

NCT ID: NCT02965274 Completed - Healthy Subjects Clinical Trials

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Fluoxetine Tablets Under Fed Conditions

Start date: November 2013
Phase: Phase 1
Study type: Interventional

Subjects to compare the single dose bioavailability of Torrent's Fluoxetine Tablets 20 mg and Sarafem® 20 mg Tablets of Warner Chilcott LLC, USA. Dosing periods of studies were separated by a washout period of 35 days.

NCT ID: NCT02965261 Completed - Healthy Subjects Clinical Trials

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Fluoxetine Tablet Under Fasting Conditions

Start date: November 2013
Phase: Phase 1
Study type: Interventional

Subjects to compare the single dose bioavailability of Torrent's Fluoxetine Tablets 20 mg and Sarafem® 20 mg Tablets of Warner Chilcott LLC, USA. Dosing periods of studies were separated by a washout period of 35 days.

NCT ID: NCT02962336 Completed - Healthy Subjects Clinical Trials

Bioequivalence Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochloride Tablets Under Fasting Conditions.

Start date: May 2011
Phase: Phase 1
Study type: Interventional

Subjects to compare the single dose bioavailability of Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg and Tribenzor® 40+10+25 mg Tablets of Daichi Sankyo Inc, USA. Dosing periods of studies were separated by a washout period of 22 days.

NCT ID: NCT02962323 Completed - Healthy Subjects Clinical Trials

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Start date: November 2009
Phase: Phase 1
Study type: Interventional

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of studies were separated by a washout period of 7 days.

NCT ID: NCT02962310 Completed - Healthy Subjects Clinical Trials

Bio Equivalence Study of Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets Under Fasting Condition.

Start date: October 2009
Phase: Phase 1
Study type: Interventional

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of studies were separated by a washout period of 7 days.

NCT ID: NCT02962258 Completed - Healthy Subjects Clinical Trials

BE Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tab - Fed Conditions

Start date: May 2011
Phase: Phase 1
Study type: Interventional

Subjects to compare the single dose bioavailability of Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets 40+10+25 mg and Tribenzor® 40+10+25 mg Tablets of Daichi Sankyo Inc, USA. Dosing periods of studies were separated by a washout period of 22 days.

NCT ID: NCT02957435 Withdrawn - Healthy Subjects Clinical Trials

Pharmacokinetics Study of Eplerenone Coated Tablets

Start date: July 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics profile of the formulation of eplerenone coated tablets in the concentration of 25mg, 50mg and 100mg (2 coated tablets of 50mg) in male and female healthy subjects under fasting condition.